These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Relationship of the antihypertensive effect of vasopressin withdrawal to sodium excretion in the Doca-salt hypertensive rat. Wang H, Wilson N, McNeill JR. Clin Invest Med; 1993 Oct; 16(5):348-57. PubMed ID: 8261688 [Abstract] [Full Text] [Related]
4. Leukotriene D4 inhibits cardiovascular responses to sympathetic stimulation, angiotensin and vasopressin in the pithed spontaneously hypertensive rats. Bayorh MH, Zukowska-Grojec Z, Kopin IJ, Feuerstein G. J Pharmacol Exp Ther; 1984 Oct; 231(1):85-90. PubMed ID: 6491978 [Abstract] [Full Text] [Related]
5. Pathogenesis of malignant hypertension: experimental evidence from the renal hypertensive rat. Möhring J. Clin Nephrol; 1975 Nov; 4(5):167-74. PubMed ID: 1192618 [Abstract] [Full Text] [Related]
6. Effects of vasopressin and V1 receptors blockade on blood pressure and heart rate in spontaneously hypertensive rats. Stepniakowski K, Lapiński M, Noszczyk B, Januszewicz A, Szczepańska-Sadowska E. Pol J Pharmacol Pharm; 1991 Nov; 43(6):487-93. PubMed ID: 1840331 [Abstract] [Full Text] [Related]
7. Studies on the pathogenesis of the malignant course of renal hypertension in rats. Möhring J, Möhring B, Petri M, Haack D, Hackenthal E. Kidney Int Suppl; 1975 Sep; ():S174-80. PubMed ID: 1059802 [No Abstract] [Full Text] [Related]
8. [The effect of parathormone on the reactivity of renal blood flow to vasopressin in normotensive and spontaneously hypertensive rats]. Brin BB, Tatrov AS. Biull Eksp Biol Med; 1991 Mar; 111(3):244-5. PubMed ID: 2054492 [Abstract] [Full Text] [Related]
12. Chronic salt loading and cardiovascular-associated changes in experimental diabetes in rats. Maeda C, Schaan B, Oliveira E, Oliveira V, De Angelis K, Irigoyen M. Clin Exp Pharmacol Physiol; 2007 Jul; 34(7):574-80. PubMed ID: 17581211 [Abstract] [Full Text] [Related]
13. [Renin-angiotensin and vasopressin in the pathogenesis of malignant hypertension]. Möhring J. Verh Dtsch Ges Kreislaufforsch; 1977 Jul; 43():157-66. PubMed ID: 349924 [No Abstract] [Full Text] [Related]
14. Renovascular hypertension: a paradigm for all hypertension. Laragh JH. J Hypertens Suppl; 1986 Oct; 4(4):S79-88. PubMed ID: 3534186 [No Abstract] [Full Text] [Related]
15. Treatment with the arginase inhibitor N(omega)-hydroxy-nor-L-arginine improves vascular function and lowers blood pressure in adult spontaneously hypertensive rat. Bagnost T, Berthelot A, Bouhaddi M, Laurant P, André C, Guillaume Y, Demougeot C. J Hypertens; 2008 Jun; 26(6):1110-8. PubMed ID: 18475148 [Abstract] [Full Text] [Related]
16. The vasoconstriction-volume spectrum in normotension and in the pathogenesis of hypertension. Laragh JH, Sealey JE, Niarchos AP, Pickering TG. Fed Proc; 1982 Jun; 41(8):2415-23. PubMed ID: 7084486 [Abstract] [Full Text] [Related]
17. Vasopressin is increased in mineralocorticoid-induced blood pressure increase in man. Haller H, Bähr V, Bock A, Distler A, Philipp T. J Hypertens Suppl; 1987 Dec; 5(5):S111-3. PubMed ID: 3327927 [Abstract] [Full Text] [Related]
18. [Blood vasopressin concentration is patients of different ages with hypertension]. Golovchenko SF. Probl Endokrinol (Mosk); 1979 Dec; 25(4):35-9. PubMed ID: 471971 [Abstract] [Full Text] [Related]
19. Osmoregulation and baroregulation of plasma vasopressin in essential hypertension. Robertson GL, Ganguly A. J Cardiovasc Pharmacol; 1986 Dec; 8 Suppl 7():S87-91. PubMed ID: 2434780 [Abstract] [Full Text] [Related]
20. Vasopressin in hypertension. Padfield PL. Am Heart J; 1977 Oct; 94(4):531-2. PubMed ID: 910687 [No Abstract] [Full Text] [Related] Page: [Next] [New Search]